Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.
about
Immunotherapy biomarkers 2016: overcoming the barriers.Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma.Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade.
P2860
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Immunological markers and clin ...... mustine in the NIBIT-M1 study.
@ast
Immunological markers and clin ...... mustine in the NIBIT-M1 study.
@en
type
label
Immunological markers and clin ...... mustine in the NIBIT-M1 study.
@ast
Immunological markers and clin ...... mustine in the NIBIT-M1 study.
@en
prefLabel
Immunological markers and clin ...... mustine in the NIBIT-M1 study.
@ast
Immunological markers and clin ...... mustine in the NIBIT-M1 study.
@en
P2093
P2860
P1433
P1476
Immunological markers and clin ...... mustine in the NIBIT-M1 study.
@en
P2093
Anna Maria Di Giacomo
Cristina Maccalli
Ester Fonsatti
Filippo Capocefalo
Giorgio Parmiani
Lorenzo Pilla
P2860
P304
P356
10.1080/2162402X.2015.1071007
P577
2015-08-12T00:00:00Z